CASC3 and Miyoshi myopathy: In subsequent time points (i.e. T3B, T3 and C2B; see, Supplementary Figure 2), we found that in most MM patients proteasome activities remained low (in both cell types) after administration of either BTZ or CFZ (Supplementary Figures 3A, 3B, 4, 6).